← Back to Screener
Clene Inc. Common Stock (CLNN)
Price$6.27
Favorite Metrics
Price vs S&P 500 (26W)-32.34%
Price vs S&P 500 (4W)0.33%
Market Capitalization$72.44M
All Metrics
Book Value / Share (Quarterly)$0.66
P/TBV (Annual)18.25x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-24.78%
Cash Flow / Share (Quarterly)$-1.71
Price vs S&P 500 (YTD)0.84%
Gross Margin (TTM)78.50%
Net Profit Margin (TTM)-13086.50%
EPS (TTM)$-2.57
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-2.57
Revenue Growth (5Y)-0.97%
EPS (Annual)$-2.65
ROI (Annual)-123.54%
Gross Margin (Annual)78.50%
Net Profit Margin (5Y Avg)-7979.03%
Cash / Share (Quarterly)$0.48
Revenue Growth QoQ (YoY)-15.38%
ROA (Last FY)-144.35%
Revenue Growth TTM (YoY)-41.52%
EBITD / Share (TTM)$-2.22
ROE (5Y Avg)-1408.09%
Operating Margin (TTM)-11541.50%
Cash Flow / Share (Annual)$-1.71
P/B Ratio16.99x
P/B Ratio (Quarterly)12.65x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)424.31x
Net Interest Coverage (TTM)-8.27x
ROA (TTM)-119.13%
EPS Incl Extra (Annual)$-2.65
Current Ratio (Annual)0.83x
Quick Ratio (Quarterly)0.80x
3-Month Avg Trading Volume0.09M
52-Week Price Return105.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.17
P/S Ratio (Annual)362.18x
Asset Turnover (Annual)0.01x
52-Week High$13.50
Operating Margin (5Y Avg)-8926.11%
EPS Excl Extra (Annual)$-2.65
CapEx CAGR (5Y)-36.90%
26-Week Price Return-25.45%
Quick Ratio (Annual)0.80x
13-Week Price Return20.35%
Total Debt / Equity (Annual)1.99x
Current Ratio (Quarterly)0.83x
Enterprise Value$84.863
Revenue / Share Growth (5Y)11.09%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-22.70%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.82x
Pretax Margin (Annual)-13086.50%
Cash / Share (Annual)$0.48
3-Month Return Std Dev87.90%
Gross Margin (5Y Avg)79.00%
Net Income / Employee (TTM)$-0
ROE (Last FY)-369.71%
Net Interest Coverage (Annual)-6.39x
EPS Basic Excl Extra (Annual)$-2.65
Receivables Turnover (TTM)6.25x
Total Debt / Equity (Quarterly)6.36x
EPS Incl Extra (TTM)$-2.57
Receivables Turnover (Annual)6.25x
ROI (TTM)-117.21%
P/S Ratio (TTM)362.18x
Pretax Margin (5Y Avg)-7990.97%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.04
Price vs S&P 500 (52W)70.37%
Year-to-Date Return4.77%
5-Day Price Return-7.87%
EPS Normalized (Annual)$-2.65
ROA (5Y Avg)-93.15%
Net Profit Margin (Annual)-13086.50%
Month-to-Date Return24.75%
Cash Flow / Share (TTM)$-0.43
EBITD / Share (Annual)$-2.22
Operating Margin (Annual)-11541.50%
LT Debt / Equity (Annual)0.53x
ROI (5Y Avg)-195.19%
LT Debt / Equity (Quarterly)1.66x
EPS Basic Excl Extra (TTM)$-2.57
P/TBV (Quarterly)2.76x
P/B Ratio (Annual)2.84x
Inventory Turnover (TTM)0.82x
Pretax Margin (TTM)-13086.50%
Book Value / Share (Annual)$2.09
Price vs S&P 500 (13W)17.97%
Beta0.89x
Revenue / Share (TTM)$0.02
ROE (TTM)-322.23%
52-Week Low$2.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CLNNClene Inc. Common Stock | 362.18x | -41.52% | 78.50% | — | $6.27 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $899.91 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $224.87 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $205.74 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $112.62 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $196.15 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $148.70 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $38.87 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $94.12 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.37 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $58.80 |
About
Clene Inc is a clinical-stage pharmaceutical company developing novel clean-surfaced nanotechnology (CSN) therapeutics for neurodegenerative diseases. The company uses its proprietary electro-crystal-chemistry platform to produce concentrated, stable nanocrystal suspensions. It operates a dietary supplements business with products including CNM-Au8, CNM-ZnA, and CNM-AgZn17.